Eli Lilly, a pharmaceutical giant that just last year occupied the ninth position, has ascended to the pinnacle of the…
Read More
The Joint Clinical Assessment: Navigating Procedural and Methodological Hurdles in EU Drug Evaluation
The advent of the Joint Clinical Assessment (JCA) process in the European Union, designed to harmonize the clinical evaluation of…
Read More
Pharma 50: Keytruda Holds Top Brand Slot, But Tirzepatide and Semaglutide Have Already Passed It at the Molecule Level in FY2025
Merck’s Keytruda (pembrolizumab) maintained its formidable position as the pharmaceutical industry’s leading brand in Fiscal Year 2025, recording an impressive…
Read More
Chiesi Acquires KalVista Pharmaceuticals for $1.9 Billion, Bolstering Rare Disease Portfolio with On-Demand HAE Treatment
In a landmark move that marks the largest acquisition in its 90-year history, Italian pharmaceutical giant Chiesi has agreed to…
Read More
Pharma 50: The 50 best-selling drugs of FY2025
The fiscal year 2025 witnessed a dramatic recalibration at the apex of the pharmaceutical industry’s sales leaderboard, characterized by a…
Read More
LEO Pharma Acquires Gene Therapy Pioneer Replay to Revolutionize Treatment for Rare Genetic Dermatological Diseases
In a landmark move poised to redefine the landscape of dermatological therapeutics, LEO Pharma, a global leader in medical dermatology,…
Read More
Bristol Myers Squibb Bets on Milvexian and Cobenfy to Drive Growth into the 2030s Amidst Patent Expiries
Bristol Myers Squibb (BMS) is strategically positioning itself for sustained growth through the 2030s, with upcoming pivotal Phase III readouts…
Read More
Eli Lilly Soars Past Expectations on Unabated Weight-Loss Drug Demand, Raises Full-Year Forecast
Eli Lilly and Company has once again demonstrated its formidable market power, reporting first-quarter 2026 sales that significantly surpassed analyst…
Read More
FDA Approves Auvelity for Alzheimer’s Disease Agitation, Offering a Novel Treatment Option
The U.S. Food and Drug Administration (FDA) has granted approval to Axsome Therapeutics’ Auvelity (dextromethorphan HBr and bupropion HCl) for…
Read More
The Staggering Cost of Fragmented Clinical Trial Management: A Deep Dive into Inefficiencies and the Promise of Unified Platforms
The global clinical trials market, a critical engine for medical advancement, is currently grappling with pervasive inefficiencies stemming from the…
Read MoreYOU MAY HAVE MISSED
